

# Clinical trials of anticoagulant for cardiovascular prevention in secondary prevention

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 anticoagulant

Trial	Treatments	Patients	Trials design and methods
<b>anticoagulant vs no anticoagulant</b>			
MacMillan , 1960 n=NA	-	-	
Borchegrevink , 1960 n=NA	-	-	
Clausen , 1961 n=NA	-	-	
Harvald , 1961 n=NA	-	-	
Conrad , 1964 n=NA	-	-	
Wasserman , 1966 n=NA	-	-	
Loeliger , 1967 n=NA	-	-	
Lovell , 1967 n=NA	-	-	
Seaman , 1969 n=NA	-	-	
Sorensen , 1969 n=NA	-	-	
Meuwisse , 1969 n=NA	-	-	
Drapkin and Merskey , 1972 n=NA	-	-	
<b>dicoumarol vs no anticoagulant</b>			
Apenstrom and Korsan-Bengtzen , 1964 n=NA follow-up:	-	-	
<b>coumarin congeners vs placebo</b>			
Sixty Plus Reinfarction , 1980 n=NA follow-up: 2 years	acenocoumarin orphenprocoumon versus placebos	elderly patients who had been on anticoagulants ever since their primary myocardial infarction	double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
<b>nicoumalone or phenprocoumon vs placebo</b>			
ASPECT , 1994 n=1700/1704 follow-up: 37 months	anticoagulant (nicoumalone or phenprocoumon) versus placebo	hospital survivors of myocardial infarction	
<b>phenprocoumon vs placebo</b>			
Breddin , 1980 n=320/309 follow-up:	-	patients who had survived a myocardial infarction for 30-42 days	double-blind
<b>warfarin vs placebo</b>			
WARIS , 1990 n=607/607 follow-up: 37 months	warfarin versus placebo	patients who had recovered from acute myocardial infarction (mean interval from the onset of symptoms to randomization, 27 days)	double-blind

## References

### MacMillan, 1960:

MACMILLAN RL, BROWN K, WATT DL Long-term anticoagulant therapy after myocardial infarction. Can Med Assoc J 1960;83:567-70 [[14419608](#)]

MACMILLAN RL, BROWN K, WATT DL Long-term anticoagulant therapy after myocardial infarction. Can Med Assoc J 1960;83:567-70 [[14419608](#)]

### Borchegrevink, 1960:

### Clausen, 1961:

CLAUSEN J, ANDERSEN PE, ANDRESEN P, GRUELUND S, HARSLOF E, ANDERSEN UH, JORGENSEN J, MOSE C [Long-term anticoagulant treatment after acute coronary occlusion. Material with complete comparison with control material]. Ugeskr Laeger 1961;123:987-94 [[13693953](#)]

### Harvald, 1961:

### Conrad, 1964:

CONRAD LL, KYRIACOPOULOS JD, WIGGINS CW, HONICK GL PREVENTION OF RECURRENCES OF MYOCARDIAL INFARCTION; A DOUBLE-BLIND STUDY OF THE EFFECTIVENESS OF LONG-TERM ORAL ANTICOAGULANT THERAPY. Arch Intern Med 1964;114:348-58 [[14171625](#)]

### Wasserman, 1966:

Wasserman AJ, Gutterman LA, Yoe KB, Kemp VE Jr, Richardson DW Anticoagulants in acute myocardial infarction. The failure of anticoagulants to alter mortality in a randomized series. Am Heart J 1966;71:43-9 [[5900864](#)]

### Loeliger, 1967:

Loeliger EA, Hensen A, Kroes F, van Dijk LM, Fekkes N, de Jonge H, Hemker HC A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1967;182:549-66 [[4862156](#)]

### Lovell, 1967:

### Seaman, 1969:

Seaman AJ, Griswold HE, Reaume RB, Ritzmann L Long-term anticoagulant prophylaxis after myocardial infarction. N Engl J Med 1969;281:115-9 [[4307139](#)] [10.1056/NEJM196907172810301](#)

### Sorensen, 1969:

Sorensen OH, Friis T, Jorgensen AW, Jorgensen MB, Nissen NI Anticoagulant treatment of acute coronary thrombosis. Acta Med Scand 1969;185:65-72 [[4185116](#)]

### Meuwisse,, 1969:

Meuwisse OJ, Vervoorn AC, Cohen O, Jordan FL, Nelemans FA Double blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1969;186:361-8 [[4985108](#)]

### Drapkin and Merskey, 1972:

Drapkin A, Merskey C Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. JAMA 1972;222:541-8 [4117261]

**Apenstrom and Korsan-Bengtson, 1964:**

ASPENSTROEM G, KORSAN-BENGTSEN K A DOUBLE BLIND STUDY OF DICUMAROL PROPHYLAXIS IN CORONARY HEART DISEASE. Acta Med Scand 1964;176:563-75 [14223532]

**Sixty Plus Reinfarction, 1980:**

A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980;2:989-94 [6107674]

**ASPECT, 1994:**

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994;343:499-503 [7906757]

**Breddin, 1980:**

Breddin K, Loew D, Lechner K, Oberla K, Walter E The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation 1980;62:V63-72 [6777073]

**WARIS, 1990:**

Smith P, Arnesen H, Holme I The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52 [2194126]

## 2 NOAC

∞

Trial	Treatments	Patients	Trials design and methods
<b>rivaroxaban vs aspirin</b>			
COMPASS (rivaroxaban alone) , 2017 [NCT01776424] n=27400 follow-up:	Rivaroxaban 2.5 mg twice daily alone versus aspirin 100 mg once daily	Patients With Coronary or Peripheral Artery Disease	
<b>rivaroxaban + aspirin vs aspirin</b>			
COMPASS (rivaroxaban + aspirin) , 2017 [NCT01776424] n=9152/9126 follow-up: 23 months	rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily) versus aspirin 100 mg once daily	Patients With Coronary or Peripheral Artery Disease	Parallel groups double-blind
<b>rivaroxaban vs placebo</b>			
COMMANDER HF ongoing [NCT01877915] n=5000 follow-up:	Rivaroxaban 2.5 mg versus placebo	Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure	

## References

COMPASS (rivaroxaban alone), 2017:

COMPASS (rivaroxaban + aspirin), 2017:

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakka Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N Engl J Med* 2017;377:1319-1330 [[28844192](#)]

**COMMANDER HF, :**

### **3 About TrialResults-center.org**

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.